These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26376695)

  • 1. Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Chen R; Fen Y; Lin X; Ma T; Cai H; Ding H
    Technol Cancer Res Treat; 2016 Dec; 15(6):815-820. PubMed ID: 26376695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.
    Ding H; Gui X; Lin X; Chen R; Ma T; Sheng Y; Cai H; Fen Y
    Technol Cancer Res Treat; 2017 Oct; 16(5):645-653. PubMed ID: 27688262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.
    Wu X; Zhou F; Ji X; Ren K; Shan Y; Mao X; Fen Y; Chen R; Ding H; Fu X
    Future Oncol; 2017 Dec; 13(29):2691-2696. PubMed ID: 28972404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
    Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
    Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
    Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival.
    Sirohi B; Ashley S; Norton A; Popat S; Hughes S; Papadopoulos P; Priest K; O'Brien M
    J Thorac Oncol; 2007 Aug; 2(8):735-40. PubMed ID: 17762340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
    Ramsden K; Laskin J; Ho C
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
    Cicènas S; Geater SL; Petrov P; Hotko Y; Hooper G; Xia F; Mudie N; Wu YL
    Lung Cancer; 2016 Dec; 102():30-37. PubMed ID: 27987585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of MAC30 Expression in Human Pure Squamous Cell Carcinomas of the Lung.
    Ding H; Gui XH; Lin XB; Chen RH; Cai HR; Fen Y; Sheng YL
    Asian Pac J Cancer Prev; 2016; 17(5):2705-10. PubMed ID: 27268655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
    Chen HH; Yan JJ; Chen WC; Kuo MT; Lai YH; Lai WW; Liu HS; Su WC
    Lung Cancer; 2012 Feb; 75(2):228-34. PubMed ID: 21788094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
    Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
    J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.